NEW YORK (GenomeWeb) – After announcing positive results for the fourth quarter of 2016, Genomic Health is now anticipating financial progress in 2017, supported by its solid breast cancer testing business, as well as the continued development of the company's newer prostate cancer arm.
Genomic Health Anticipates Progress for Prostate Cancer Business, Hints at Other New Tests This Year
Premium
Get the full story with
360Dx Premium
Only $95 for the
first 90 days*
A trial upgrade to 360Dx Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Already a 360Dx Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.